8 completed, 1 terminated, 1 unknown. 10 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 8, Terminated 1, Unknown 1 |
| Phase 2 | 4 | Completed 4 |
Follow HCV: new trials by email Literature Review of HCV trials Research Report on HCV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children Sofosbuvir 200 MG Oral Tablet plus Daclatasvir 30 mg Oral tablets - HCV | Phase 3 | Unknown | Ain Shams University | 30 | 2022-06-05 | 2023-05-11 |
| Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters Sofosbuvir +daclatasvir+ simeprevir+Ribavirin - Male Infertility, HCV | Phase 2 / Phase 3 | Completed | Benha University | 200 | 2022-03-01 | 2023-02-08 |
| Utilization of Hepatitis C Positive Kidneys in Negative Recipients Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET] - Kidney Transplant, Hepatitis C | Phase 2 / Phase 3 | Completed | Ohio State University | 54 | 2019-03-22 | 2023-09-13 |
| Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects. Ravidasvir, Danoprevir, Ritonavir - HCV | Phase 2 / Phase 3 | Completed | Ascletis Pharmaceuticals Co., Ltd. | 425 | 2017-07-01 | 2020-07-28 |
| Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects Glecaprevir/Pibrentasvir (G/P) 300mg/120mg, Ribavirin 200Mg Tablet - Hepatitis C, HCV | Phase 3 | Completed | University of Florida | 177 | 2017-04-20 | 2020-02-26 |
| A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2) glecaprevir/pibrentasvir - Chronic Hepatitis C, HCV | Phase 3 | Completed | AbbVie | 100 | 2016-04-22 | 2021-07-13 |
| A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection ABT-493/ABT-530 - Chronic Hepatitis C, Hepatitis C Virus | Phase 3 | Completed | AbbVie | 703 | 2015-10-01 | 2021-07-13 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy ABT-493, ABT-530, ribavirin (RBV), ABT-493/ABT-530 - Chronic Hepatitis C, Hepatitis C Virus | Phase 2 / Phase 3 | Completed | AbbVie | 141 | 2015-04-01 | 2017-09-15 |
| Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt 2 DAA, RBV - HCV, Hepatitis C Infection | Phase 3 | Completed | AbbVie | 160 | 2014-11-04 | 2021-07-30 |
| Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures Eltrombopag, Placebo - Non-alcoholic Steatohepatitis, Chronic Liver Disease | Phase 3 | Terminated | GlaxoSmithKline | 292 | 2008-06-01 | 2018-10-12 |
Hepatitis C (7) · Hepatitis C, Chronic (3) · Acquired Immunodeficiency Syndrome (1) · Fibrosis (1) · HIV Infections (1) · Hepatitis B (1) · Infertility, Male (1) · Jacobs syndrome (1) · Liver Diseases (1) · Non-alcoholic Fatty Liver Disease (1) · Thrombocytopenia (1)
Blood-Borne Infections (7) · Communicable Diseases (7) · Digestive System Diseases (7) · Flaviviridae Infections (7) · Hepatitis (7) · Hepatitis, Viral, Human (7) · Infections (7) · RNA Virus Infections (7) · Virus Diseases (7) · Liver Diseases (6) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Chronic Disease (3) · Disease Attributes (3) · Hepatitis, Chronic (3)
glecaprevir (5) · glecaprevir and pibrentasvir (5) · pibrentasvir (5) · Ribavirin (3) · Sofosbuvir (2) · Tablets (2) · Ritonavir (1) · daclatasvir (1) · danoprevir (1) · eltrombopag (1) · ombitasvir (1) · ravidasvir (1) · sofosbuvir-velpatasvir drug combination (1) · velpatasvir (1)
AbbVie (4) · Ain Shams University (1) · Ascletis Pharmaceuticals Co., Ltd. (1) · Benha University (1) · GlaxoSmithKline (1) · Ohio State University (1) · University of Florida (1)
United States (3) · Egypt (2) · Argentina (1) · Belgium (1) · Canada (1) · China (1) · France (1) · India (1) · Italy (1) · Pakistan (1) · Poland (1) · Russia (1) · South Korea (1) · Spain (1) · Taiwan (1)
David R Nelson, MD (1) · Manal H. El-Sayed, MD (1) · Reem Daloul, MD (1) · Sarah Kopecky-Bromberg, PhD (1) · Susan Rhee, MD (1) · Yahong Chen, Master (1)
PMID 30012435, PMID 30923816, PMID 30977945, PMID 31568620, PMID 22913681, PMID 28128852, PMID 30529905, PMID 30868245, PMID 31401140, PMID 34023351
2015 (3)